Relevant bibliographies by topics / Mesenchymal stem cell therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Mesenchymal stem cell therapy'

Author: Grafiati
Published: 10 January 2023
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Mesenchymal stem cell therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Mesenchymal stem cell therapy"

1

Mundra, Vaibhav, Ivan C. Gerling, and Ram I. Mahato. "Mesenchymal Stem Cell-Based Therapy." Molecular Pharmaceutics 10, no. 1 (December 24, 2012): 77–89. http://dx.doi.org/10.1021/mp3005148.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Choi, Yeong-Hoon, Andreas Kurtz, and Christof Stamm. "Mesenchymal Stem Cells for Cardiac Cell Therapy." Human Gene Therapy 22, no. 1 (January 2011): 3–17. http://dx.doi.org/10.1089/hum.2010.211.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mihaylova, Zornitsa. "Stem cells and mesenchymal stem cell markers." International Journal of Medical Science and Clinical invention 6, no. 08 (August 6, 2019): 4544–47. http://dx.doi.org/10.18535/ijmsci/v6i8.03.

Full text
Abstract:
Stem cells are undifferentiated cell type characterized by colonogenic ability, self-renewal and multi-lineage differentiation. They are classified into the following categories: embryonic stem cells [ESC], somatic stem cells [or adult stem cells] and induced pluripotent stem cells [iPSC]. Stem cells represent area of interest for wide range of scientists, as they are promising tool for regenerative therapy. Their differentiation ability is significantly affected by various factors of the local environment. Additional research will provide more information about the optimal cell culture conditions when stem cells are cultivated for clinical purpose, to avoid side effects like uncontrolled cell proliferation and premature differentiation.
APA, Harvard, Vancouver, ISO, and other styles
4

Haseli, Mahsa, and Akbar Esmaeili. "Concerns About Mesenchymal Stem Cell Therapy." International Clinical Neuroscience Journal 8, no. 1 (December 30, 2020): 1–2. http://dx.doi.org/10.34172/icnj.2021.01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dazzi, Francesco, and Nicole J. Horwood. "Potential of mesenchymal stem cell therapy." Current Opinion in Oncology 19, no. 6 (November 2007): 650–55. http://dx.doi.org/10.1097/cco.0b013e3282f0e116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Horwitz, E. M. "Mesenchymal and nonhematopoietic stem-cell therapy." Cytotherapy 4, no. 6 (October 2002): 501. http://dx.doi.org/10.1080/146532402761624610.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Afizah, Hassan, and James Hoi Po Hui. "Mesenchymal stem cell therapy for osteoarthritis." Journal of Clinical Orthopaedics and Trauma 7, no. 3 (July 2016): 177–82. http://dx.doi.org/10.1016/j.jcot.2016.06.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Abbasi, Ardeshir. "Mesenchymal stem cells: applications in immuno-cell therapy." Journal of Immunological Sciences 2, no. 4 (August 1, 2018): 1–3. http://dx.doi.org/10.29245/2578-3009/2018/4.1149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Samper, E., A. Diez-Juan, J. A. Montero, and P. Sepúlveda. "Cardiac Cell Therapy: Boosting Mesenchymal Stem Cells Effects." Stem Cell Reviews and Reports 9, no. 3 (February 16, 2012): 266–80. http://dx.doi.org/10.1007/s12015-012-9353-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Brown, Christina, Christina McKee, Shreeya Bakshi, Keegan Walker, Eryk Hakman, Sophia Halassy, David Svinarich, Robert Dodds, Chhabi K. Govind, and G. Rasul Chaudhry. "Mesenchymal stem cells: Cell therapy and regeneration potential." Journal of Tissue Engineering and Regenerative Medicine 13, no. 9 (July 25, 2019): 1738–55. http://dx.doi.org/10.1002/term.2914.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Mesenchymal stem cell therapy"

1

Che, Mohamad Che Anuar. "Human embryonic stem cell-derived mesenchymal stem cells as a therapy for spinal cord injury." Thesis, University of Glasgow, 2014. http://theses.gla.ac.uk/7047/.

Full text
Abstract:
Traumatic injury to the spinal cord interrupts ascending and descending pathways leading to severe functional deficits of sensory motor and autonomic function which depend on the level and severity of the injury. There are currently no effective therapies for treating such injuries and the adult central nervous system has very limited capacity for repair so that recovery is very limited and functional deficits are usually permanent. Cell transplantation is a potential therapy for spinal cord injury and a range of cell types are being investigated as candidates. Mesenchymal stem cells (MSCs) obtained from bone marrow are one cell type quite extensively studied. When transplanted into animal models of spinal cord injury these cells are reported to affect various aspects of repair and in some cases to improve functional outcome according to behavioural measures. However, the use of these cells has several limitations including the need for an invasive harvesting procedure, variability in cell quality and slow expansion in culture. This project therefore had two main aims: Firstly to investigate whether MSC-like cells closely equivalent to bone marrow derived MSCs could be reliably and consistently differentiated from human embryonic stem cells (hESCs) in order to provide an “off the shelf” cellular therapy product for spinal cord injury and secondly, to transplant such cells into animal models of spinal cord injury in order to, determine whether hESC-derived MSCs replicate or improve on the repair mechanisms reported for bone marrow MSCs.
APA, Harvard, Vancouver, ISO, and other styles
2

Mead, Ben. "Mesenchymal stem cell therapy for traumatic and degenerative eye disease." Thesis, University of Birmingham, 2015. http://etheses.bham.ac.uk//id/eprint/6295/.

Full text
Abstract:
Aims The aim of this PhD research project was to investigate the application of dental pulp stem cells (DPSC) as a treatment for traumatic and degenerative eye diseases. The accuracy and reliability of counting retinal ganglion cells (RGC) in radial retinal section was also assessed. Methods Numbers of RGC in radial retinal sections were compared to numbers in retinal wholemounts. DPSC were cultured with RGC and survival and neuritogenesis were quantified. DPSC were also transplanted intravitreally into rat models of optic neuropathy (optic nerve crush) and glaucoma and surviving RGC and regenerated axons were quantified in radial retinal sections. Results Quantifying RGC in radial retinal sections was as reliable and accurate as the current gold standard Thus, retinal wholemounts with Brn3a proved to be the most reliable marker for RGC. DPSC protected RGC from optic nerve crush-/glaucoma-induced death, promoting significant regeneration of RGC axons in the former and preserving visual function (as measured by electroretinography) in the latter. The mechanism of action, as determined in vitro, appeared to be through the secretion of multiple neurotrophic factors (NTF). Conclusions In conclusion, DPSC is a potent cell therapy in the treatment of traumatic and degenerative eye disease.
APA, Harvard, Vancouver, ISO, and other styles
3

Nili, Ahmadabadi Elham. "Development of a novel mesenchymal stromal cell (MSC) therapy for repairing the cornea." Thesis, Queensland University of Technology, 2018. https://eprints.qut.edu.au/122897/1/Elham_Nili%20Ahmadabadi_Thesis.pdf.

Full text
Abstract:
This thesis has produced advances in our understanding of the biology and potential clinical application of stem cells to aid the treatment of patients with severe eye injuries. This research evaluated the therapeutic potential of a stem cell (called Mesenchymal Stromal Cells (MSCs)) isolated from the peripheral margin of the cornea, known as the limbus. Firstly, a method for routinely isolation and propagation of human limbal MSCs was optimized. Subsequently, the performance of those cells on a silk fibroin membrane was examined.
APA, Harvard, Vancouver, ISO, and other styles
4

Nie, Yingjie. "Defective dendritic cells and mesenchymal stromal cells in systemic lupus erythematosus and the potential of mesenchymal stromal cells as cell-therapy." Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B43278681.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wu, Pensée. "Muscular dystrophy cell therapy : an in utero approach using human fetal mesenchymal stem cells." Thesis, Imperial College London, 2009. http://hdl.handle.net/10044/1/4726.

Full text
Abstract:
Duchenne muscular dystrophy (DMD) is the most prevalent genetic neuromuscular disorder and affects 1 in 3,500 live male births. Lack of the protein dystrophin in muscle fibres causes permanent muscle damage, is lethal and despite various potential therapeutic strategies aimed at restoring dystrophin expression, has no cure. As DMD affects all skeletal muscles as well as the heart, a systemic treatment would be necessary and in utero stem cell transplantation is a promising way of achieving this. The identification of human fetal mesenchymal stem cells (hfMSC) in early gestation fetal blood offers the prospect of allogeneic or autologous cell therapy, while intrauterine administration would capitalise on ontological opportunities unique to the developing fetus. The aim of the study was to improve hfMSC engraftment and contribution to skeletal muscle fibres following intrauterine transplantation (IUT) in a mouse model of DMD. My project demonstrated that hfMSCs are easily isolated and expandable with the ability to undergo myogenesis in vitro. HfMSCs differentiated into mature myotubes following exposure to galectin-1 conditioned medium, while galectin-1 transduced hfMSCs showed significantly higher expression of myogenic markers compared to non-transduced hfMSCs. Co-culture experiments provided an in vitro model to explore the underlying mechanism for muscle differentiation of hfMSCs following IUT. HfMSCs were able to form chimeric myotubes by fusing with myoblasts isolated from E15 mouse embryos, evidence that they should be able to fuse with developing muscle fibres in vivo. Engraftment and differentiation into muscle fibres of hfMSCs injected intra-peritoneally into E15 mouse embryos in vivo was enhanced by using immunodeficient dystrophic host mice, postnatal muscle injury and additional neonatal hfMSC transplantation following IUT. In conclusion, my thesis supports the use of hfMSC as an attractive source for cell therapy and provides the background for further studies to optimise their engraftment and differentiation to underpin future clinical applications.
APA, Harvard, Vancouver, ISO, and other styles
6

Loebinger, M. R. "Mesenchymal stem cells as vectors for anti-tumour therapy." Thesis, University College London (University of London), 2009. http://discovery.ucl.ac.uk/18556/.

Full text
Abstract:
Cancer is a leading cause of mortality throughout the world and new treatments are urgently needed. Recent studies suggest that bone marrow-derived mesenchymal stem cells (MSCs) home to and incorporate within tumour tissue. This property can be utilised to deliver targeted anticancer therapies. This thesis describes the production of MSCs engineered to express TNF-related apoptosis-inducing ligand (TRAIL), a transmembrane protein that causes selective apoptosis of tumour cells. Human MSCs were transduced with TRAIL and the IRES-GFP reporter gene using a lentiviral vector, under the control of a tetracycline promoter. Transduced and activated MSCs caused lung, breast, squamous, and cervical cancer cell apoptosis in vitro. In vivo, the cells were able to specifically home to tumours and both significantly reduce tumour growth, and eliminate metastatic disease. The data included in this thesis demonstrates for the first time a significant reduction in metastatic tumour burden with frequent eradication of metastases using inducible TRAIL-expressing MSCs. This has a wide potential therapeutic role, which includes the treatment of both primary tumours and their metastases, possibly as an adjuvant therapy in clearing micrometastatic disease following primary tumour resection.
APA, Harvard, Vancouver, ISO, and other styles
7

Ullah, Mujib [Verfasser]. "Molecular characterization of human mesenchymal stem cell differentiation to identify biomarkers for quality assurance in stem cell therapy / Mujib Ullah." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2014. http://d-nb.info/1047579197/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Song, Chao. "Using Mesenchymal Stem Cells As Vehicles for Anit-tumor Therapy." Thesis, Queen's University Belfast, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.501407.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Santos, José Luís da Silva. "Functionalization of dendrimers for improved gene delivery to mesenchymal stem cell." Doctoral thesis, Universidade da Madeira, 2009. http://hdl.handle.net/10400.13/29.

Full text
Abstract:
Disease, injury, and age problems compromise human quality of life and continuously motivate the search for new and more efficacious therapeutic approaches. The field of Tissue Regeneration and Engineering has greatly evolved over the last years, mainly due to the combination of the important advances verified in Biomaterials Science and Engineering with those of Cell and Molecular Biology. In particular, a new and promising area arose – Nanomedicine – that takes advantage of the extremely small size and especial chemical and physical properties of Nanomaterials, offering powerful tools for health improvement. Research on Stem Cells, the self-renewing progenitors of body tissues, is also challenging to the medical and scientific communities, being expectable the appearance of new and exciting stem cell-based therapies in the next years. The control of cell behavior (namely, of cell proliferation and differentiation) is of key importance in devising strategies for Tissue Regeneration and Engineering. Cytokines, growth factors, transcription factors and other signaling molecules, most of them proteins, have been identified and found to regulate and support tissue development and regeneration. However, the application of these molecules in long-term regenerative processes requires their continuous presence at high concentrations as they usually present short half-lives at physiological conditions and may be rapidly cleared from the body. Alternatively, genes encoding such proteins can be introduced inside cells and be expressed using cell’s machinery, allowing an extended and more sustained production of the protein of interest (gene therapy). Genetic engineering of stem cells is particularly attractive because of their self-renewal capability and differentiation potential. For Tissue Regeneration and Engineering purposes, the patient’s own stem cells can be genetically engineered in vitro and, after, introduced in the body (with or without a scaffold) where they will not only modulate the behavior of native cells (stem cell-mediated gene therapy), but also directly participate in tissue repair. Cells can be genetically engineered using viral and non-viral systems. Viruses, as a result of millions of years of evolution, are very effective for the delivery of genes in several types of cells, including cells from primary sources. However, the risks associated with their use (like infection and immunogenic reactions) are driving the search for non-viral systems that will efficiently deliver genetic material into cells. Among them, chemical methods that are promising and being investigated use cationic molecules as carriers for DNA. In this case, gene delivery and gene expression level remain relatively low when primary cells are used. The main goal of this thesis was to develop and assess the in vitro potential of polyamidoamine (PAMAM) dendrimers based carriers to deliver genes to mesenchymal stem cells (MSCs). PAMAM dendrimers are monodispersive, hyperbranched and nanospherical molecules presenting unique characteristics that make them very attractive vehicles for both drug and gene delivery. Although they have been explored for gene delivery in a wide range of cell lines, the interaction and the usefulness of these molecules in the delivery of genes to MSCs remains a field to be explored. Adult MSCs were chosen for the studies due to their potential biomedical applications (they are considered multipotent cells) and because they present several advantages over embryonic stem cells, such as easy accessibility and the inexistence of ethical restrictions to their use. This thesis is divided in 5 interconnected chapters. Chapter I provides an overview of the current literature concerning the various non-viral systems investigated for gene delivery in MSCs. Attention is devoted to physical methods, as well as to chemical methods that make use of polymers (natural and synthetic), liposomes, and inorganic nanoparticles as gene delivery vectors. Also, it summarizes the current applications of genetically engineered mesenchymal stem cells using non-viral systems in regenerative medicine, with special focus on bone tissue regeneration. In Chapter II, the potential of native PAMAM dendrimers with amine termini to transfect MSCs is evaluated. The level of transfection achieved with the dendrimers is, in a first step, studied using a plasmid DNA (pDNA) encoding for the β-galactosidase reporter gene. The effect of dendrimer’s generation, cell passage number, and N:P ratio (where N= number of primary amines in the dendrimer; P= number of phosphate groups in the pDNA backbone) on the level of transfection is evaluated, being the values always very low. In a second step, a pDNA encoding for bone morphogenetic protein-2, a protein that is known for its role in MSCs proliferation and differentiation, is used. The BMP-2 content produced by transfected cells is evaluated by an ELISA assay and its effect on the osteogenic markers is analyzed through several classical assays including alkaline phosphatase activity (an early marker of osteogenesis), osteocalcin production, calcium deposition and mineralized nodules formation (late osteogenesis markers). Results show that a low transfection level is enough to induce in vitro osteogenic differentiation in MSCs. Next, from Chapter III to Chapter V, studies are shown where several strategies are adopted to change the interaction of PAMAM dendrimers with MSCs cell membrane and, as a consequence, to enhance the levels of gene delivery. In Chapter III, generations 5 and 6 of PAMAM dendrimers are surface functionalized with arginine-glycine-aspartic acid (RGD) containing peptides – experiments with dendrimers conjugated to 4, 8 and 16 RGD units were performed. The underlying concept is that by including the RGD integrin-binding motif in the design of the vectors and by forming RGD clusters, the level of transfection will increase as MSCs highly express integrins at their surface. Results show that cellular uptake of functionalized dendrimers and gene expression is enhanced in comparison with the native dendrimers. Furthermore, gene expression is dependent on both the electrostatic interaction established between the dendrimer moiety and the cell surface and the nanocluster RGD density. In Chapter IV, a new family of gene delivery vectors is synthesized consisting of a PAMAM dendrimer (generation 5) core randomly linked at the periphery to alkyl hydrophobic chains that vary in length and number. Herein, the idea is to take advantage of both the cationic nature of the dendrimer and the capacity of lipids to interact with biological membranes. These new vectors show a remarkable capacity for internalizing pDNA, being this effect positively correlated with the –CH2– content present in the hydrophobic corona. Gene expression is also greatly enhanced using the new vectors but, in this case, the higher efficiency is shown by the vectors containing the smallest hydrophobic chains. Finally, chapter V reports the synthesis, characterization and evaluation of novel gene delivery vectors based on PAMAM dendrimers (generation 5) conjugated to peptides with high affinity for MSCs membrane binding - for comparison, experiments are also done with a peptide with low affinity binding properties. These systems present low cytotoxicity and transfection efficiencies superior to those of native dendrimers and partially degraded dendrimers (Superfect®, a commercial product). Furthermore, with this biomimetic approach, the process of gene delivery is shown to be cell surface receptor-mediated. Overall, results show the potential of PAMAM dendrimers to be used, as such or modified, in Tissue Regeneration and Engineering. To our knowledge, this is the first time that PAMAM dendrimers are studied as gene delivery vehicles in this context and using, as target, a cell type with clinical relevancy. It is shown that the cationic nature of PAMAM dendrimers with amine termini can be synergistically combined with surface engineering approaches, which will ultimately result in suitable interactions with the cytoplasmic membrane and enhanced pDNA cellular entry and gene expression. Nevertheless, the quantity of pDNA detected inside cell nucleus is always very small when compared with the bigger amount reaching cytoplasm (accumulation of pDNA is evident in the perinuclear region), suggesting that the main barrier to transfection is the nuclear membrane. Future work can then be envisaged based on the versatility of these systems as biomedical molecular materials, such as the conjugation of PAMAM dendrimers to molecules able to bind nuclear membrane receptors and to promote nuclear translocation.
Orientadores: Helena Maria Pires Gaspar Tomás e Pedro Lopes Granja
APA, Harvard, Vancouver, ISO, and other styles
10

Yanai, Goichi. "Electrofusion of Mesenchymal Stem Cells and Islet Cells for Diabetes Therapy: A Rat Model." Kyoto University, 2015. http://hdl.handle.net/2433/200315.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Mesenchymal stem cell therapy"

1

Chase, Lucas G., and Mohan C. Vemuri, eds. Mesenchymal Stem Cell Therapy. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-200-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gross, Gerhard, and Thomas Häupl. Stem cell-dependent therapies: Mesenchymal stem cells in chronic inflammatory disorders. Berlin: De Gruyter, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhao, Robert Chunhua. Essentials of mesenchymal stem cell biology and its clinical translation. Dordrecht: Springer, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Xie, Xiaojie, and Wang Jian'an. Mesenchymal stem cells for the heart: From bench to bedside. Hangzhou: Zhejiang University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mesenchymal stem cell assays and applications. New York: Humana Press/Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vemuri, Mohan, Lucas G. Chase, and Mahendra S. Rao, eds. Mesenchymal Stem Cell Assays and Applications. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-999-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gugjoo, Mudasir Bashir, and Amar Pal, eds. Mesenchymal Stem Cell in Veterinary Sciences. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-6037-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

V, Greer Erik, ed. Stem cell therapy. New York: Nova Science Publishers, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pham, Phuc Van. Liver, lung and heart regeneration. Cham: Springer, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zhao, Robert Chunhua, ed. Essentials of Mesenchymal Stem Cell Biology and Its Clinical Translation. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-6716-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Mesenchymal stem cell therapy"

1

Cook, Matthew M. "Mesenchymal Stem Cells and Haematopoietic Stem Cell Culture." In Mesenchymal Stem Cell Therapy, 161–72. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-200-1_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Van de Walle, Gerlinde R., Catharina De Schauwer, and Lisa A. Fortier. "Mesenchymal Stem Cell Therapy." In Equine Clinical Immunology, 297–310. Chichester, UK: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119086512.ch31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sasaki, Masanori, and Osamu Honmou. "Mesenchymal Stem Cells." In Cell Therapy Against Cerebral Stroke, 147–56. Tokyo: Springer Japan, 2017. http://dx.doi.org/10.1007/978-4-431-56059-3_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Alvarez-Viejo, Maria, and Khawaja Husnain Haider. "Mesenchymal Stem Cells." In Handbook of Stem Cell Therapy, 1–37. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-6016-0_6-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Alvarez-Viejo, Maria, and Khawaja Husnain Haider. "Mesenchymal Stem Cells." In Handbook of Stem Cell Therapy, 127–62. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-2655-6_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jung, Yunjoon, and Jan A. Nolta. "Genetically Engineered Mesenchymal Stem Cells for Cell and Gene Therapy." In Mesenchymal Stem Cell Therapy, 321–54. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-200-1_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Baranyi, Lajos, and Boro Dropulic. "Advances in Lentiviral Vector-based Cell Therapy with Mesenchymal Stem Cells." In Mesenchymal Stem Cell Therapy, 271–320. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-200-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Santos, F. Dos, P. Z. Andrade, C. L. da Silva, and J. M. S. Cabral. "Scaling-up Ex Vivo Expansion of Mesenchymal Stem/Stromal Cells for Cellular Therapies." In Mesenchymal Stem Cell Therapy, 1–14. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-200-1_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ringdén, Olle. "Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease and Graft Failure After Hematopoietic Stem Cell Transplantation and Future Challenges." In Mesenchymal Stem Cell Therapy, 173–205. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-200-1_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Molendijk, Ilse, Daan W. Hommes, and Marjolijn Duijvestein. "Mesenchymal Stromal Cell Therapy in Crohn’s Disease." In Mesenchymal Stem Cell Therapy, 207–15. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-200-1_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Mesenchymal stem cell therapy"

1

Onay, Ozge Surmeli, Ayse Neslihan Tekin, Damla Gunes, Ozge Aydemir, Sevilhan Artan, and Yusuf Aydemir. "GP248 Mesenchymal stem cell therapy in microvillus inclusion disease." In Faculty of Paediatrics of the Royal College of Physicians of Ireland, 9th Europaediatrics Congress, 13–15 June, Dublin, Ireland 2019. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-epa.307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bonfield, T. L., L. Auster, V. Ragavapuram, D. Fletcher, M. Sutton, R. Somoza, J. Kurtzberg, M. K. Glassberg Csete, and A. I. Caplan. "Mesenchymal Stem Cell Therapy and Chronic Non-Tuberculous Mycobacterium Infection." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2657.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chen, Jing, and Sihong Wang. "Thermal Effects on Osteogenesis of Human Mesenchymal Stem Cells." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80885.

Full text
Abstract:
Intensive studies were reported on the osteogenesis of mesenchymal stem cells (MSC) using chemicals and mechanical loading. However, the maturity of differentiated osteoblasts is not same as that of isolated adult osteoblasts. Thermal treatment could be a missing factor in stem cell differentiation. It was reported that mild heat stimulated bone growth in animal experiments [1–2]. Thermal treatment is also used as a therapy to promote bone repair after injury [3]. In addition, hot shower daily is recommended to osteoarthritis patients. However, the mechanisms for the heat-induced osteogenesis are not completely known and the thermal regulation of human mesenchymal stem cells (hMSCs) differentiation is not well studied. In this study, the direct effects of mild heat shock (HS) on the differentiation of hMSCs into osteoblasts in self-assembling peptide hydrogel were investigated.
APA, Harvard, Vancouver, ISO, and other styles
4

Doherty, Declan, Lydia Roets, Rebecca Delaney, Anna Krasnodembskaya, Marcus A. Mall, Clifford C. Taggart, and Sinead Weldon. "Mesenchymal stem cell therapy in a model of chronic inflammatory lung disease." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3855.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Duarte, Gabriela Guy, Daniel Gonçalves de Oliveira, Felipe de Oliveira Breder, Guilherme Augusto Netto Nacif, and Ivan Magalhães Viana. "Efficacy of mesenchymal stem cells in the treatment of ischemic stroke." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.327.

Full text
Abstract:
Background: Ischemic stroke is one of the main causes of long-term disability in adults. In the search for therapies for neurological sequelae after stroke, several studies have been investigating the use of stem cells, especially mesenchymal stem cells (MSC). Objectives: To evaluate the efficacy of stem cell therapy in patients with neurological deficits due to stroke. Methods: A literature review was conducted based on clinical studies published on PubMed and Cochrane databases between 2013 and 2021. The search strategy (mesenchymal stem cells) AND (stroke) was used and 4 articles were selected. Results: In the selected studies, we observed the use of autologous or allogeneic MSCs, derived from bone marrow or umbilical cord. The cells were transplanted using intravenous, intra-arterial or intracerebral routes. The articles demonstrated safety in the use of MSC, with no reports of serious adverse effects causally related to cell therapy. The evaluation of efficacy was performed through the analysis of neurological condition scales such as the NIHSS, the modified Rankin Scale and the Fugl-Meyer Scale. The trials showed improvements in at least one of the scales after therapy, and the benefits focused, mainly, on the motor function of the patients. MSC are associated with the secretion of factors that promote inflammatory immunomodulation, angiogenesis and neurogenesis, contributing to brain repair. Conclusions: The use of MSCs in the treatment of ischemic stroke is safe and has therapeutic potential for repairing ischemic brain tissue. However, further studies are needed to prove the efficacy of MSCs in the rehabilitation of stroke.
APA, Harvard, Vancouver, ISO, and other styles
6

Kumar, Arun, and Binil Starly. "Modeling Human Mesenchymal Stem Cell Expansion in Vertical Wheel Bioreactors Using Lactate Production Rate in Regenerative Medicine Biomanufacturing." In ASME 2016 11th International Manufacturing Science and Engineering Conference. American Society of Mechanical Engineers, 2016. http://dx.doi.org/10.1115/msec2016-8787.

Full text
Abstract:
Stem cells are critical components of regenerative medicine therapy. However, the therapy will require millions to billions of therapeutic stem cells. To address the need, we have recently cultured stem cells in 3D microgels and used them as a vehicle for cell expansion within a low shear stress rotating wheel type bioreactor within a 500ml volumetric setting. This study specifically highlights the cell encapsulation in microbead process, harvesting and operation of microbeads within a dynamic bioreactor environment. We have specifically encapsulated stem cells (human adipose derived) into microbeads prepared from alginate hydrogels via an electrostatic jetting process. This study highlights the effect of fabrication process parameters on end-point biological quality measures such as stem cell count and viability. We were able to maintain a >80% viability during the 21 day static culture period. We have also measured the concentration of metabolites produced during the expansion, specifically lactate production measured during specific time points within culture inside the rotating wheel bioreactor Future work will need to address predicting yields in higher volume settings, efficiency of harvest and a more detailed description of the hydrodynamics affecting stem cell growth.
APA, Harvard, Vancouver, ISO, and other styles
7

Salehi, Nasrin, and Ching-An Peng. "Abstract 5352: Mesenchymal stem cell as delivery carrier for prodrug gene therapy against colorectal cancer cell." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5352.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Discher, Dennis, and Adam Engler. "Mesenchymal Stem Cell Injection After Myocardial Infarction Improves Myocardial Compliance." In ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-176754.

Full text
Abstract:
Cellular therapy for myocardial injury has improved ventricular function in both animal and clinical studies, though the mechanism of benefit is unclear. This study was undertaken to examine the effects of cellular injection after infarction on myocardial elasticity. Coronary artery ligation of Lewis rats was followed by direct injection of human mesenchymal stem cells (MSC) into the acutely ischemic myocardium. Two weeks post-infarct, myocardial elasticity was mapped by atomic force microscopy. MSC-injected hearts near the infarct region were two-fold stiffer than myocardium from non-infarcted animals but softer than myocardium from vehicle-treated infarcted animals. After eight weeks, the following variables were evaluated: MSC engraftment and left ventricular geometry by histologic methods; cardiac function with a pressure-volume conductance catheter; myocardial fibrosis by Masson trichrome staining; vascularity by immunohistochemistry; and apoptosis by TUNEL assay. The human cells engrafted and expressed a cardiomyocyte protein but stopped short of full differentiation and did not stimulate significant angiogenesis. MSC-injected hearts showed significantly less fibrosis than controls, as well as less left ventricular dilation, reduced apoptosis, increased myocardial thickness, and preservation of systolic and diastolic cardiac function. In summary, MSC injection after myocardial infarction did not regenerate contracting cardiomyocytes but reduced the stiffness of the subsequent scar and attenuated post-infarction remodeling, preserving some cardiac function. Improving scarred heart muscle compliance could be a functional benefit of cellular cardiomyoplasty.
APA, Harvard, Vancouver, ISO, and other styles
9

Guillamat-Prats, Raquel, Marta Camprubí-Rimblas, Ferranda Puig, Raquel Herrero, Anna Serrano-Mollar, Jessica Tijero, Maria Nieves Gómez, Lluís Blanch, and Antonio Artigas. "Cell therapy for the treatment of acute lung injury: Alveolar type II cells or mesenchymal stem cells?" In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa945.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wingate, Kathryn, Yan Tan, and Wei Tan. "The Effects of Mechanical and Chemical Stimuli on Mesenchymal Stem Cell Vascular Trans-Differentiation and Paracrine Signaling." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14742.

Full text
Abstract:
Mesenchymal Stem Cells (MSCs) show great promise for the treatment of cardiovascular diseases by tissue engineering and cell therapy. MSCs are particularly useful for vascular therapies as they are easily obtainable, allogenic, trans-differentiate into specific vascular cells, and assist in regenerating vascular tissue through paracrine signaling. [1] However, the mechanisms which direct MSC trans-differentiation and paracrine signaling are not well defined. [2] Incorrect differentiation of MSC can lead to catastrophic side effects such as the development of a dysfunctional endothelium. [3] To safely utilize these cells for the treatment of vascular diseases it is critical to understand the underlying mechanisms that direct MSC differentiation and paracrine signaling.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Mesenchymal stem cell therapy"

1

Karp, Jeffrey, and John Isaacs. Mesenchymal Stem Cell-Based Therapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2014. http://dx.doi.org/10.21236/ada612823.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ponnazhagan, Selvarangan. Systemic and Gene Modified Mesenchymal Stem Cell Therapy for Metastatic Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2009. http://dx.doi.org/10.21236/ada510963.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ponnazhagan, Selvarangan. Systemic and Gene Modified Mesenchymal Stem Cell Therapy for Metastatic Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2007. http://dx.doi.org/10.21236/ada470809.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, W. P. Mesenchymal Stem Cell Therapy for Nerve Regeneration and Immunomodulation after Composite Tissue Allotransplantation. Fort Belvoir, VA: Defense Technical Information Center, August 2012. http://dx.doi.org/10.21236/ada574699.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lee, W. P. Mesenchymal Stem Cell Therapy for Nerve Regeneration and Immunomodulation After Composite Tissue Allotransplantation. Fort Belvoir, VA: Defense Technical Information Center, February 2011. http://dx.doi.org/10.21236/ada559244.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Xiaoyuan. Mesenchymal Stem Cell as Targeted-Delivery Vehicle in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2008. http://dx.doi.org/10.21236/ada487022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cheng, Zhen. Mesenchymal Stem Cell as Targeted-Delivery Vehicle in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2010. http://dx.doi.org/10.21236/ada538054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Donohue, Henry J., Christopher Niyibizi, and Alayna Loiselle. Induced Pluripotent Stem Cell Derived Mesenchymal Stem Cells for Attenuating Age-Related Bone Loss. Fort Belvoir, VA: Defense Technical Information Center, September 2013. http://dx.doi.org/10.21236/ada606237.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Donahue, Henry J. Induced Pluripotent Stem Cell Derived Mesenchymal Stem Cells for Attenuating Age-Related Bone Loss. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada581680.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cui, Yan. Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cell. Fort Belvoir, VA: Defense Technical Information Center, April 2008. http://dx.doi.org/10.21236/ada483255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Mesenchymal stem cell therapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography